Nitrolingual Spray (Glyceryl Trinitrate)

Glyceryl trinitrate is a nitric‑oxide donor. After administration, it is converted to nitric oxide, which activates soluble guanylate cyclase in vascular smooth muscle. This raises cyclic GMP levels, causing relaxation of smooth muscle, vasodilation of veins and arteries, reduced cardiac preload and afterload, and increased myocardial oxygen delivery.

The specific dose and frequency of Nitrolingual Spray are determined by the prescribing clinician based on the patient’s condition, severity of angina, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

The safety of glyceryl trinitrate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nitrolingual Spray delivers glyceryl trinitrate via an oromucosal spray, offering rapid onset of action compared with oral nitrates that require gastrointestinal absorption. Unlike long‑acting oral agents, the spray is useful for acute relief and for short‑term prophylaxis before exertion, providing a convenient, fast‑acting alternative.

Store Nitrolingual Spray at room temperature, preferably below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the nozzle is capped when not in use to maintain product stability.

The spray is applied to the inside of the mouth, typically under the tongue or against the buccal mucosa. The patient should hold the spray for a few seconds to allow absorption, avoid swallowing immediately, and remain seated or lying down for a short period to reduce the risk of dizziness.

The most serious risks include severe hypotension, syncope, myocardial infarction in susceptible individuals, and rare cases of methemoglobinemia or severe allergic reactions. Patients should be instructed to seek immediate medical attention if they experience fainting, chest pain that does not improve, or signs of an allergic response.

Nitrolingual Spray should be avoided in patients with known hypersensitivity to glyceryl trinitrate or other organic nitrates, in those who have taken phosphodiesterase‑5 inhibitors within the past 24–48 hours, and in individuals with severe anemia, increased intracranial pressure, or uncontrolled hypotension unless specifically directed by a physician.